Example: Heart Attack

Clinical Trials Sponsored by Hoffmann-La Roche

Total 2365 results

NCT05878769

Not yet recruiting

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
NCT05872763

Not yet recruiting

A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

Carcinoma, Non-Small-Cell Lung
NCT05861999

Not yet recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Muscular Atrophy, Spinal
NCT05862285

Not yet recruiting

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study (UmbrellaMAX)

Cancer
NCT05861986

Not yet recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

Muscular Atrophy, Spinal
NCT05852691

Not yet recruiting

A Study of RO7247669 + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Breast Cancer
NCT05849857

Not yet recruiting

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries (MERLIN)

Lymphoma, Follicular
NCT05846594

Not yet recruiting

A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer (L1st)

Metastatic Lung Cancer Metastatic Gastrointestinal Cancer
NCT05835986

Not yet recruiting

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
NCT05808764

Not yet recruiting

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (Pupfish)

Muscular Atrophy, Spinal
NCT05805501

Recruiting

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma
NCT05797610

Recruiting

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

Primary IgA Nephropathy
NCT05798156

Not yet recruiting

Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive Large B-cell Lymphoma Ineligible for R-CHOP (R-Pola-Glo)

Lymphoma, Large B-Cell, Diffuse
NCT05789082

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of GDC-6036 in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Non-Small Cell Lung Cancer
NCT05786716

Recruiting

DETERMINE Trial Treatment Arm 4: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE)

Colorectal Neoplasms Ovarian Neoplasms Solid Tumor Gallbladder Neoplasms Prostatic Neoplasm Pancreatic Neoplasm Lung Neoplasm Haematological Malignancy Urinary Bladder Neoplasm Skin Neoplasm
NCT05775289

Recruiting

A Study of RO7247669 Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
NCT05773196

Recruiting

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study (SAN-09611)

Huntington Disease Huntington's Dementia Huntington Disease, Late Onset Huntington; Dementia (Etiology)
NCT05769959

Recruiting

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer
NCT05770544

Recruiting

DETERMINE Trial Treatment Arm 3: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers. (DETERMINE)

Glioma Melanoma Neoplasms by Histologic Type Lymphoproliferative Disorders Neoplasms by Site Cancer Brain Neoplasms Solid Tumor Malignant Neoplasm Malignancy
NCT05770102

Not yet recruiting

DETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition (DETERMINE)

Melanoma Neoplasms by Histologic Type Lymphoproliferative Disorders Neoplasms by Site Cancer Colorectal Neoplasms Endometrial Neoplasms Malignant Neoplasm Malignancy
NCT05770037

Recruiting

DETERMINE Trial Treatment Arm 1: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type Lymphoma Lymphoproliferative Disorders Neoplasms by Site Renal Cell Carcinoma Cancer Solid Tumor Anaplastic Large Cell Lymphoma Neuroblastoma Malignant Neoplasm
NCT05768178

Recruiting

DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)

Glioma Melanoma Carcinoma, Non-Small-Cell Lung Multiple Myeloma Colorectal Neoplasms Ovarian Neoplasms Solid Tumor Thyroid Cancer, Papillary Thyroid Carcinoma, Anaplastic Laryngeal Neoplasms
NCT05763576

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B
NCT05756907

Not yet recruiting

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Advanced Solid Tumor Platinum-resistant Ovarian Cancer
NCT05722886

Recruiting

DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)

Solid Tumor Haematological Malignancy
NCT05704361

Recruiting

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous RO7121932 in Participants With Multiple Sclerosis.

Multiple Sclerosis
NCT05694013

Recruiting

Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice (ORIGAMA)

Cancer
NCT05686551

Recruiting

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Huntington Disease
NCT05661188

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal
NCT05661578

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)

PD-L1-selected Solid Tumors
NCT05646862

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer
NCT05645692

Recruiting

A Study of RO7247669 Alone or in Combination With Tiragolumab vs Atezolizumab in Participants With Untreated Locally Advanced or Metastatic Urothelial Cancer

Urothelial Cancer
NCT05642325

Recruiting

RO7200220 in Participants With Uveitic Macular Edema (Sandcat)

Uveitic Macular Edema
NCT05642312

Recruiting

A Study to Investigate RO7200220 in Participants With Uveitic Macular Edema (Meerkat)

Uveitic Macular Edema
NCT05634499

Recruiting

A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer (EndomERA)

Endometrial Cancer

Clinical Trials Sponsored by Hoffmann-La Roche

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations